Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program

Journal of Lower Genital Tract Disease

Volumn 11, Issue 4, 2007, Pages 258-264

  Lonky, Neal M ^a,b,c   Hunter, Mark I ^b   Sadeghi, Mashod ^a   Edwards, Gary ^a   Bajamundi, Kathy ^a   Monk, Bradley J ^b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Cervical cancer; Cocollection; Cost effectiveness; Human papillomavirus; Hybrid Capture; Pap smear; Screening

Indexed keywords

ADULT; ARTICLE; CANCER CYTODIAGNOSIS; CANCER SCREENING; COCULTURE; COLPOSCOPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MANAGED CARE; PAPANICOLAOU TEST; RETROSPECTIVE STUDY; SQUAMOUS CELL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; CALIFORNIA; COST-BENEFIT ANALYSIS; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; MEDICAL AUDIT; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 34948823806     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/LGT.0b013e318057f319     Document Type: Article

References (16)

1. Davies P, Arbyn M, Dillner J, Kitchener HC, Meijer CJ, Ronco G, et al. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer 2006;118:791-6.
2. Brink AA, Snijders PJ, Meijer CJ, Berkhof J, Verheijen RH. HPV testing in cervical screening. Best Pract Res Clin Obstet Gynaecol 2006;20:253-66.
3. Cochand-Priollet B, Cartier I, de Cremoux P, Le Gales C, Ziol M, Molinie V, et al. Cost-effectiveness of liquid-based cytology with or without Hybrid-Capture II HPV test compared with conventional Pap smears: a study by the French Society of Clinical Cytology. Diagn Cytopathol 2005;33:338-43.
4. Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst 2006;98:92-100.
5. Melnikow J, Birch S. Human papillomavirus triage of atypical squamous cells of undetermined significance: cost-effective, but at what cost? J Natl Cancer Inst 2006;98:82-3.
6. Mahoney MC, Saslow D, Cohen CJ. ACS guideline for the early detection of cervical cancer. Am Fam Physician 2003;67:1677-8. 1680 [discussion 1680].
7. ACOG Committee on Practice Bulletins - Gynecology. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists, Number 45, August 2003: cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol 2003;102:417-27.
8. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. JAMA 2002;287:2120-9.
9. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
10. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
11. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-6.
12. Cox JT. Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management. Obstet Gynecol Surv 2006;61:S15-S25.
13. Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-9.
14. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103:619-31.
15. Bidus MA, Maxwell GL, Kulasingam S, Rose GS, Elkas JC, Chernofsky M, et al. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet Gynecol 2006;107:997-1005.
16. Lonky NM, Felix JC, Naidu YM, Wolde-Tsadik G. Triage of atypical squamous cells of undetermined significance with Hybrid Capture II: colposcopy and histologic human papillomavirus correlation. Obstet Gynecol 2003;101:481-9.